Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093399 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CHRNB2CHRNA4HRH3L3MBTL1 | |
| SCHEMBL31093396 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CHRNB2CHRNA4HRH3L3MBTL1 | |
| SCHEMBL29607692 | 0.88 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL28473856 | 0.88 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL14641819 | 0.81 | SMN1; SMN2 (0.44) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL5048925 | 0.81 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL5048184 | 0.80 | HRH3 (0.50) | ALDH1A1CHRNB2CHRNA4HRH3L3MBTL1 | |
| SCHEMBL13536859 | 0.80 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL9321540 | 0.79 | SMN1; SMN2 (0.45) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL7845108 | 0.78 | HRH3 (0.50) | ALDH1A1CHRNB2CHRNA4HRH3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024167927-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | REVERIE LABS, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-2709997-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2603500-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8729078-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729078-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729078-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2709997-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| CN-1759116-A | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | PFIZER (US) | 2006-04-12 | — | — | CN | disclosed |
| CN-1745078-A | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORP (FI) | 2006-03-08 | — | — | CN | disclosed |
| EP-1608648-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | Pfizer Products Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1583759-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2005-10-12 | — | — | EP | disclosed |
| US-20050026922-A1 | For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| WO-2004081007-A1 | PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004063191-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2004-07-29 | — | — | WO | disclosed |
| EP-0609811-B1 | Process for preparing 2-chloro-5-aminomethyl-pyridines | KOEI CHEMICAL CO (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5424437-A | Process for preparing a 2-chloro-5-aminomethyl-pyridine | KOEI CHEMICAL CO., LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
| EP-0609811-A1 | Process for preparing 2-chloro-5-aminomethyl-pyridine | KOEI CHEMICAL CO., Ltd. (JP) | 1994-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026922-A1 | For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine | GRM7, GRIN2C, HTR7 | ALDH1A1 718/4885CHRNB2 116/4885CHRNA4 59/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | ALDH1A1 4422/4885CHRNB2 4010/4885CHRNA4 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.